CRIS Share Price

Open 2.11 Change Price %
High 2.20 1 Day -0.01 -0.47
Low 2.05 1 Week 0.26 14.13
Close 2.10 1 Month 0.38 22.09
Volume 1349644 1 Year 0.48 29.63
52 Week High 3.72
52 Week Low 1.47
CRIS Important Levels
Resistance 2 2.24
Resistance 1 2.18
Pivot 2.12
Support 1 2.02
Support 2 1.96
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
DCTH 0.16 -33.33%
FTR 1.22 8.93%
FTR 1.22 8.93%
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
More..
NASDAQ USA Top Gainers Stocks
OPXAW 0.12 200.00%
AVEO 1.25 71.23%
LOCM 0.09 50.00%
MYRX 0.09 50.00%
SNCR 16.24 33.33%
QUIK 1.60 31.15%
WRES 0.09 28.57%
IIN 8.35 27.48%
IIN 8.35 27.48%
IIN 8.35 27.48%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
TOPS 0.80 -66.67%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Curis, Inc. (NASDAQ: CRIS)

CRIS Technical Analysis 1.5
As on 23rd Jun 2017 CRIS Share Price closed @ 2.10 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.48 & Buy for SHORT-TERM with Stoploss of 2.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRIS Target for June
1st Target up-side 2.18
2nd Target up-side 2.52
3rd Target up-side 2.85
1st Target down-side 1.24
2nd Target down-side 0.9
3rd Target down-side 0.57
CRIS Other Details
Segment EQ
Market Capital 288233760.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.curis.com
CRIS Address
CRIS
4 Maguire Road
Lexington, MA 02421
United States
Phone: 617-503-6500
Fax: 617-503-6501
CRIS Latest News
Interactive Technical Analysis Chart Curis, Inc. ( CRIS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Curis, Inc.
CRIS Business Profile
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company�s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).